Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
The new functionality complements Parse’s existing Evercode immune products
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Subscribe To Our Newsletter & Stay Updated
